Patient characteristics
| . | Tt-BuCy . | ATG-BuCy . | P . |
|---|---|---|---|
| No. of patients | 30 | 51 | |
| Follow up, mo* | 36.8 (17.3-80.5) | 16.9 (7.4-30.7) | <.001 |
| Age, y* | 3.1 (0.9-6.4) | 4.8 (1.4-14.5) | .002 |
| Sex ratio, male/female | 23/7 | 31/20 | .222 |
| Height-for-age z-score* | −1.085 (−2.90 to 0.93) | −1.380 (−3.08 to 1.33) | .328 |
| Body mass index-for-age z-score* | −0.29 (−2.85 to 1.58) | −0.85 (−3.88 to 1.32) | .110 |
| Consanguinity | 13 of 27 (3 NA) (48%) | 25 of 46 (5 NA) (54%) | .636 |
| No. of previous transfusions | 30 (6-128) | 42 (3-338) | .026 |
| Donor age | 7.1 (1.5-22.3) | 6.8 (1.1-37.4) | .907 |
| Matched-related donor type | Sibling in 29 of 30 (1 first-degree cousin) | Sibling in 50 of 51 (1 mother) | 1.000 |
| No sibling sex mismatch | 12 of 29 (41%) | 21 of 50 (42%) | 1.000 |
| Sister donor to brother | 13 of 29 (45%) | 18 of 50 (36%) | .480 |
| Brother donor to sister | 4 of 29 (14%) | 11 of 50 (22%) | .553 |
| Donor thalassemia minor | 23 of 30 (77%) | 37 of 51 (73%) | .796 |
| Major ABO mismatch | 7 of 30 (23%) | 8 of 51 (16%) | .394 |
| Ferritin at BMT, ng/mL* | 2282 (591-8008) | 1920 (376 to 6171) | .354 |
| Hydroxyurea therapy prior to BMT | 1 of 30 (3%) | 21 of 51 (41%) | <.001 |
| Liver size, cm from costal margin | all ≤2 cm | all ≤2 cm | |
| Spleen size, cm from costal margin | 28 ≤ 2 cm, 1 = 3 cm, 1 NA | 49 ≤ 2 cm, 1 = 3 cm, 1 = 4 cm | |
| Splenectomy | 1 (3%) | 0 | |
| SGPT, IU/L (HCV-negative patients)* | 49.5 (12-149) | 32 (11 to 151) | .008 |
| HCV positive | 7 of 30 (23%) | 5 of 51 (10%) | .108 |
| SGPT, IU/L (HCV-positive patients)* | 161 (23-537) | 90 (35 to 118) | .268 |
| . | Tt-BuCy . | ATG-BuCy . | P . |
|---|---|---|---|
| No. of patients | 30 | 51 | |
| Follow up, mo* | 36.8 (17.3-80.5) | 16.9 (7.4-30.7) | <.001 |
| Age, y* | 3.1 (0.9-6.4) | 4.8 (1.4-14.5) | .002 |
| Sex ratio, male/female | 23/7 | 31/20 | .222 |
| Height-for-age z-score* | −1.085 (−2.90 to 0.93) | −1.380 (−3.08 to 1.33) | .328 |
| Body mass index-for-age z-score* | −0.29 (−2.85 to 1.58) | −0.85 (−3.88 to 1.32) | .110 |
| Consanguinity | 13 of 27 (3 NA) (48%) | 25 of 46 (5 NA) (54%) | .636 |
| No. of previous transfusions | 30 (6-128) | 42 (3-338) | .026 |
| Donor age | 7.1 (1.5-22.3) | 6.8 (1.1-37.4) | .907 |
| Matched-related donor type | Sibling in 29 of 30 (1 first-degree cousin) | Sibling in 50 of 51 (1 mother) | 1.000 |
| No sibling sex mismatch | 12 of 29 (41%) | 21 of 50 (42%) | 1.000 |
| Sister donor to brother | 13 of 29 (45%) | 18 of 50 (36%) | .480 |
| Brother donor to sister | 4 of 29 (14%) | 11 of 50 (22%) | .553 |
| Donor thalassemia minor | 23 of 30 (77%) | 37 of 51 (73%) | .796 |
| Major ABO mismatch | 7 of 30 (23%) | 8 of 51 (16%) | .394 |
| Ferritin at BMT, ng/mL* | 2282 (591-8008) | 1920 (376 to 6171) | .354 |
| Hydroxyurea therapy prior to BMT | 1 of 30 (3%) | 21 of 51 (41%) | <.001 |
| Liver size, cm from costal margin | all ≤2 cm | all ≤2 cm | |
| Spleen size, cm from costal margin | 28 ≤ 2 cm, 1 = 3 cm, 1 NA | 49 ≤ 2 cm, 1 = 3 cm, 1 = 4 cm | |
| Splenectomy | 1 (3%) | 0 | |
| SGPT, IU/L (HCV-negative patients)* | 49.5 (12-149) | 32 (11 to 151) | .008 |
| HCV positive | 7 of 30 (23%) | 5 of 51 (10%) | .108 |
| SGPT, IU/L (HCV-positive patients)* | 161 (23-537) | 90 (35 to 118) | .268 |
Bold type indicates statistical significance.
HCV, hepatitis C virus; NA, not available.
Median (range).